For decades, cardiology and endocrinology treated calcium as a one-dimensional problem: too little caused osteoporosis, too much caused arterial plaque. The discovery that a single vitamin-dependent protein — Matrix Gla Protein — actively pulls calcium out of arterial walls and helps deposit it into bone has reframed this entirely. The vitamin in question is K2, and specifically the long-chain menaquinone MK-7, which possesses a half-life and tissue distribution profile that the more familiar vitamin K1 simply cannot match.
What Is Vitamin K2 (MK-7)?
Vitamin K2 refers to a family of fat-soluble menaquinones (MK-n), distinguished from vitamin K1 (phylloquinone) by an unsaturated isoprenoid side chain. The number following “MK” denotes how many isoprene units are attached. MK-4 is produced endogenously in limited quantities, while longer-chain forms — MK-7, MK-8, and MK-9 — are bacterial fermentation products found in cheeses and, most famously, the Japanese fermented soybean dish natto.[1]
MK-7 has become the form of clinical interest because its long isoprenoid tail confers a serum half-life of roughly 72 hours, compared with 1–2 hours for K1. This extended pharmacokinetic profile allows MK-7 to reach extrahepatic tissues — vascular smooth muscle, bone, and cartilage — where vitamin K-dependent proteins outside the coagulation cascade reside.[1]
How MK-7 Works
Gamma-Carboxylation: Vitamin K2 functions as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which converts specific glutamate residues on vitamin K-dependent proteins into gamma-carboxyglutamate (Gla) residues. These Gla residues create calcium-binding pockets that are essential for protein function. Without adequate K2, these proteins circulate in their inactive, uncarboxylated form.[2]
Matrix Gla Protein Activation: Matrix Gla Protein (MGP) is synthesized by vascular smooth muscle cells and chondrocytes. In its fully carboxylated form (cMGP), it binds calcium ions and bone morphogenetic protein-2, preventing the nucleation of hydroxyapatite crystals within the arterial media. Uncarboxylated MGP (ucMGP) cannot perform this function, and circulating dephosphorylated-uncarboxylated MGP (dp-ucMGP) is now an established biomarker of vascular vitamin K status.[3]
Osteocalcin Activation: In parallel, K2 carboxylates osteocalcin — a protein secreted by osteoblasts that binds calcium and hydroxyapatite, anchoring the mineral matrix within bone. Uncarboxylated osteocalcin (ucOC) is associated with reduced bone mineral density and increased fracture risk, while carboxylated osteocalcin (cOC) correlates with improved skeletal calcium incorporation.[4]
The Calcium Paradox Resolved: The simultaneous activation of MGP in the vasculature and osteocalcin in bone explains the so-called calcium paradox — the clinical observation that populations with low K2 intake show concurrent arterial calcification and osteoporosis despite adequate or excessive calcium consumption. Adequate MK-7 effectively redirects calcium handling, pulling it away from soft tissue deposition and toward skeletal mineralization.[3]
Clinical Evidence
Arterial Stiffness Reduction: The landmark three-year, double-blind, placebo-controlled trial by Knapen and colleagues randomized 244 healthy postmenopausal women to 180 µg MK-7 daily or placebo. The MK-7 group demonstrated a statistically significant reduction in carotid-femoral pulse wave velocity and the Stiffness Index β, with the most pronounced effects in women whose baseline arterial stiffness was elevated. Circulating dp-ucMGP fell by approximately 50% in the treatment arm.[5]
Coronary Artery Calcification: The Rotterdam Study, a prospective population-based cohort following 4,807 subjects, found that the highest tertile of dietary menaquinone intake was associated with a 52% reduction in severe aortic calcification and a 57% reduction in coronary heart disease mortality compared with the lowest tertile. Vitamin K1 intake showed no such association, underscoring the tissue-specific importance of the longer-chain menaquinones.[6]
Bone Mineral Density: In the same Knapen three-year trial, MK-7 supplementation slowed the age-related decrease in bone mineral content and bone mineral density at the lumbar spine and femoral neck, and significantly decreased the loss of vertebral height in the lower thoracic region. Carboxylated osteocalcin increased and uncarboxylated osteocalcin decreased proportionally to dose.[5]
Biomarker Response: A dose-response study by Theuwissen and colleagues established that 180 µg of MK-7 daily was sufficient to significantly improve the carboxylation status of MGP and osteocalcin in healthy adults, while lower doses (10–90 µg) produced only partial effects. This has become the de facto reference dose in subsequent clinical work.[7]
Safety Profile
Vitamin K2 has an exceptional safety record. No tolerable upper intake level has been established by the Institute of Medicine because no toxicity has been demonstrated even at supraphysiologic doses. Unlike vitamin K1, MK-7 does not interfere significantly with hepatic clotting factor synthesis at nutritional doses, though patients on vitamin K antagonists such as warfarin must avoid supplementation or coordinate dosing carefully with their anticoagulation provider, since any vitamin K intake will antagonize the drug’s mechanism.[1]
Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban do not interact with vitamin K, and emerging evidence suggests that patients on long-term warfarin may paradoxically suffer accelerated vascular calcification precisely because the drug inhibits MGP carboxylation alongside the intended clotting factors — a concern that has prompted reconsideration of long-term warfarin use in certain populations.[3]
MK-7 vs Other Vitamin K Forms
MK-7 vs K1 (Phylloquinone): Vitamin K1, abundant in leafy greens, is preferentially taken up by the liver to support clotting factor synthesis. Its short half-life and hepatic affinity mean little reaches peripheral tissues. MK-7’s longer half-life and lower hepatic clearance permit meaningful extrahepatic delivery — the critical difference for MGP and osteocalcin activation.[1]
MK-7 vs MK-4: MK-4 has been studied at pharmacologic doses (45 mg/day) in Japan for osteoporosis, where it received regulatory approval. However, MK-4 has a serum half-life of only 1–2 hours, requiring divided dosing and high quantities. MK-7 achieves comparable or superior carboxylation status at doses three orders of magnitude lower (180 µg vs 45,000 µg) due to its sustained serum presence.[7]
MK-7 vs Calcium Supplementation Alone: Meta-analyses of calcium supplementation without co-administration of vitamin K2 have raised concerns about increased cardiovascular event rates, presumably because supplemental calcium can be deposited in soft tissue when MGP carboxylation is suboptimal. The mechanistic rationale for pairing calcium and vitamin D supplementation with MK-7 — to ensure that absorbed calcium is directed toward bone rather than vasculature — is increasingly recognized in preventive cardiology and bone health protocols.[3]
References
- Schurgers LJ, Vermeer C. “Determination of phylloquinone and menaquinones in food: effect of food matrix on circulating vitamin K concentrations.” Haemostasis. 2000;30(6):298-307.
- Berkner KL. “The vitamin K-dependent carboxylase.” Annual Review of Nutrition. 2005;25:127-149.
- Schurgers LJ, Cranenburg EC, Vermeer C. “Matrix Gla-protein: the calcification inhibitor in need of vitamin K.” Thrombosis and Haemostasis. 2008;100(4):593-603.
- Gundberg CM, Lian JB, Booth SL. “Vitamin K-dependent carboxylation of osteocalcin: friend or foe?” Advances in Nutrition. 2012;3(2):149-157.
- Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. “Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.” Osteoporosis International. 2013;24(9):2499-2507.
- Geleijnse JM, Vermeer C, Grobbee DE, et al. “Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study.” Journal of Nutrition. 2004;134(11):3100-3105.
- Theuwissen E, Magdeleyns EJ, Braam LA, et al. “Vitamin K status in healthy volunteers.” Food & Function. 2014;5(2):229-234.
